BioSight Ltd.

www.biosight-pharma.com

High-Tech Company

Acquired by Ayala Pharmaceuticals

Graduated from: Trendlines Incubators

TECH VERTICALS

MedTech, Oncology, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	1999
Number of Employees	11
Reg. Number:	abCDe

DESCRIPTION

BioSight is a pharmaceutical development company focused on the development of therapeutics to enable safer and more effective treatment for life-threatening diseases. The lead product is aspacytarabine (BST-236) for treatment of Acute Myeloid Leukemia (AML) and other hematological diseases

TECHNOLOGY

Aspacytarabine (BST-236) is a novel pro-drug of the chemotherapeutic drug cytarabine. Cytarabine has been the backbone of first-line therapy for AML for the past 40 years, however, it is associated with severe bone marrow, gastrointestinal, and neurological toxicities, which significantly limit its use, especially in older and medically unfit patients. Aspacytarabine is designed to enable delivery of high cytarabine doses to leukemia cells with lower systemic exposure to the free drug and relative sparing of normal tissues. As such, aspacytarabine is positioned to become the new therapeutic backbone for AML, particularly for delivering high doses of cytarabine to medically unfit or older adults.

Products and Phases

Product	Phase
Aspacytarabine (BST-236)	Phase III
Aspacytarabine (BST-236 ) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Aspacytarabine has been granted FDA Fast Track Designation for first-line treatment of AML patients unfit for standard chemotherapy, and Orphan Drug designations from the FDA and EMA in AML, as well as Orphan Drug designation in MDS from the FDA.

	TARGET MARKETS
	Leukemia patients and other hematological diseases.

CONTACT INFO

Expand / Collapse All

Main Address: Airport City, Israel

Address	3 Hayarden St.
POB	1083
City	Airport City
Country	Israel
Zip	7019802

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Dr. Liat Flaishon	VP, Medical Affairs	Pluri (Director of Business Development)
Dr. Shoshi Tessler	VP, R&D
Dr. Margarita Shumilov	Director, CMC & QA
Dr. Stela Gengrinovitch	Co-Founder
Mr. Mark Gengrinovitch	Co-Founder	Saturas (VP, R&D)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Head of Pharma, Arkin Bio Ventures
abC Defghij	Board Member	Venture Advisor, Israel Biotech Fund
abC Defghij	Board Member	Entrepreneur, Investor, Philanthropist
abC Defghij	Board Member	Managing Partner, Israel Biotech Fund
abC Defghij	Board Member	CFO, CyanVac LLC

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Jul. 27, 2023

R&D

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Third Round - Extended

Dec. 02, 2020

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Institutional Investor	abCDe
abC Defghij	Institutional Investor	abCDe

Third Round

Mar. 12, 2020

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Family Office	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Secondary Deal

Jun. 06, 2017

R&D

abCDe

Second Round

May. 16, 2016

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Family Office	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

First Round - Extended

Aug. 11, 2014

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Family Office	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

First Round

Jul. 30, 2008

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe	Led the round
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Seed - Extended

Jul. 28, 2004

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Angel Club/ Group	abCDe
abC Defghij	Investment Company	abCDe

Seed

Oct. 01, 1999

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe	R&D Grant
abC Defghij	Incubator	abCDe	Holdings sold to Arkin Bio Ventures for $1.3m.

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2019

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe